Resectable Hepatocellular Carcinoma Clinical Trial
Official title:
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Hepatocellular Carcinoma (ATHENA)
This study explores the potential values of a new blood test approach to detect measurable residual disease or early coming back of cancer (recurrence)/cancer growing, spreading, or getting worse (progression) in patients with liver cancer that can be removed by surgery (resectable). The development of novel cancer biomarkers for liver cancer may help in clinical decision making and lead to improvements in patient outcomes by facilitating prediction of the response to specific treatments, improved monitoring of patients on treatment, and better prognostication of patient outcomes, thus improving stratification for clinical trials.
PRIMARY OBJECTIVES: I. To isolate plasma deoxyribonucleic acid (DNA) methylation panel from the peripheral blood of treated patients with hepatocellular carcinoma that will correlate with disease progression or measurable residual disease. II. To correlate the mutations/ DNA methylation in peripheral blood with those identified in parallel tumor samples from the same patients with hepatocellular (HCC). OUTLINE: Patients undergo collection of blood samples at 4-6 weeks prior to surgery/ablation and at 12 weeks, 6, 12, 18 and 24 months after surgery/ablation. Patients' previously collected tissue samples are analyzed. Patients' medical records are also reviewed at baseline, 4-6 weeks prior to surgery/ablation, 12 weeks, 6, 12, 18 and 24 months after surgery/ablation, and then every 6 months for 3 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 | |
| Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04857684 -
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
|
Early Phase 1 | |
| Recruiting |
NCT04701060 -
Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05578430 -
AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
|
Phase 2 | |
| Recruiting |
NCT02379377 -
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
|
Phase 1 | |
| Recruiting |
NCT04721132 -
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
|
Phase 2 | |
| Completed |
NCT06013657 -
Surgical Resection for Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05519410 -
Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04834986 -
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05701488 -
SIRT With Tremelimumab and Durvalumab for Resectable HCC
|
Phase 1 | |
| Withdrawn |
NCT04965714 -
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05807776 -
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
|
Phase 2 |